| | | | | | | | | | |
|
Dockets Management
|
| Dockets Entered On
July 10, 2006
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1998N-0046
|
| Comprehensive List of Current Guidance Documents at FDA
|
|
|
| 2000D-1318
|
| Chronic Cutaneous Ulcer/Burn Wounds--Products for Treatment
|
|
|
| 2001D-0220
|
| Biological Prod Deviation Reporting for Blood & Plasma Estab
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| 2004D-0369
|
| Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by Bioengineered Plants Intended for Food Use
|
|
|
| 2005D-0022
|
| International Conference on Harmonisation; Draft Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals
|
|
|
| 2005D-0288
|
| International Conference on Harmonisation; Guidance on Q9 Quality Risk Management
|
|
|
| 2005D-0356
|
| Guidance for Industry: Questions and Answers Regarding the Final Rule on Establishment and Maintenance of Records
|
|
|
| 2005D-0385
|
| Guidance for Industry on Using Electronic Means to Distribute Certain Product Information
|
|
|
| 2005N-0262
|
| Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality Assessment System; Notice of Pilot Program
|
|
|
| 2005N-0413
|
| Assessing Consumer Perceptions of Health Claims; Public Meeting; Request for Comments
|
|
|
| 2005N-0437
|
| Medical Gas Containers and Closures; Current Good Manufacturing
|
|
|
| 2005P-0139
|
| Withdraw approvals of certain herdwide/flockwide uses of critically and highly important antibiotics pursuant to guidance #152
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| 2006D-0172
|
| Guidance for Clinical Investigators, Institutional Review Boards and Sponsors Process for Handling Referrals to FDA Under 21 CFR 50.54 : Additional Safeguards for Children in Clinical Investigations
|
|
|
|
| 2006D-0190
|
| Guidance for Industry and Food and Drug Administration Staff; Class II Special Controls Guidance Document: Olfactory Test Device; Availability
|
|
|
| 2006N-0104
|
| Agency Information Collection Activities: Proposed Collection; Comment Request; Requirements for Submission of Labeling for Human Prescription Drugs and Biologics in Electronic Format
|
|
|
| 2006N-0107
|
| FDA-Regulated Products Containing Nanotechnology Materials
|
|
|
| 2006P-0146
|
| Amend Reg. for Prescription Drug Advertising to Establish Separate Criteria for Practitioner-Directed & Consumer-Directed Advertising and Establish Advisory Committee
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
| 2006P-0158
|
| Revoke regulations that provided for the inclusion and addition of sucralose as a non-nutritive sweetener in food
|
|
|
| 2006P-0209
|
| Safety or Efficacy of Diastat (diazepam rectal gel), 5 mg/ml, 10mg/2 ml, 15 mg/3 ml and 20 mg/4 ml
|
|
|
| 2006P-0242
|
| Approval of any Budesonide Inhalation Suspension Product using Pulmicort Respules
|
|
|
| 2006P-0245
|
| Exclusivity Determination for Risperidone
|
|
|
| 2006P-0249
|
| Refain from approving all abbreviated applications for generic enrofloxacin that purport to copy Bayer's Baytril 100 Injectable Solution
|
|
|
| 2006P-0251
|
| Label change or removal from the market of the psychotropic drug Depakote
|
|
|
| 2006V-0216
|
| Laser Light Show
|
|
|
| 1996V-0138
|
| Laser Light Show
|
|
|
| VRA 6
|
| FDA/CDRH to Strictly F/X, LLC
|
| Vol #:
|
| 1
|
|
| | | | | | | | |
|
|
| 1998N-0046
|
| Comprehensive List of Current Guidance Documents at FDA
|
|
|
| EC 10
|
| Mr. Dave Lowe
|
| Vol #:
|
| 2
|
|
|
| 2000D-1318
|
| Chronic Cutaneous Ulcer/Burn Wounds--Products for Treatment
|
|
|
| EC 1
|
| Mr. Dave Lowe
|
| Vol #:
|
| 2
|
|
|
| 2001D-0220
|
| Biological Prod Deviation Reporting for Blood & Plasma Estab
|
|
|
| EMC 3
|
| Plasma Protein Therapeutics Association (PPTA)
|
| Vol #:
|
| 1
|
|
|
| EMC 4
|
| Plasma Protein Therapeutics Association (PPTA)
|
| Vol #:
|
| 1
|
|
|
| EMC 5
|
| Plasma Protein Therapeutics Association (PPTA)
|
| Vol #:
|
| 1
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
| EMC 670
|
| Calorie Control Council
|
| Vol #:
|
| 10
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| EMC 1321
|
| E. LaFayette
|
| Vol #:
|
| 12
|
|
|
| EMC 1322
|
| B. Westlake
|
| Vol #:
|
| 12
|
|
|
| 2004D-0369
|
| Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by Bioengineered Plants Intended for Food Use
|
|
|
| EMC 1567
|
| B. Sachau
|
| Vol #:
|
| 22
|
|
|
| 2005D-0022
|
| International Conference on Harmonisation; Draft Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals
|
|
|
| EC 3
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2005D-0288
|
| International Conference on Harmonisation; Guidance on Q9 Quality Risk Management
|
|
|
| EC 5
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2005D-0356
|
| Guidance for Industry: Questions and Answers Regarding the Final Rule on Establishment and Maintenance of Records
|
|
|
| EC 4
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2005D-0385
|
| Guidance for Industry on Using Electronic Means to Distribute Certain Product Information
|
|
|
| EC 12
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2005N-0262
|
| Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality Assessment System; Notice of Pilot Program
|
|
|
| EC 13
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| EC 14
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2005N-0413
|
| Assessing Consumer Perceptions of Health Claims; Public Meeting; Request for Comments
|
|
|
| EMC 5
|
| E. Bernstein
|
| Vol #:
|
| 2
|
|
|
| EMC 6
|
| K. Chen
|
| Vol #:
|
| 2
|
|
|
| 2005N-0437
|
| Medical Gas Containers and Closures; Current Good Manufacturing
|
|
| | | | | | | | |
|
|
| EC 609
|
| Ms. Jeanette Howard
|
| Vol #:
|
| 3
|
|
|
| EC 610
|
| University of Massachusetts, Dept of Family Med.
|
| Vol #:
|
| 3
|
|
|
| EC 611
|
| Mrs. Brenda Parker
|
| Vol #:
|
| 3
|
|
|
| EC 612
|
| Ms. Sarah Lombardo
|
| Vol #:
|
| 3
|
|
|
| EC 613
|
| Mrs. Debra Roundy
|
| Vol #:
|
| 3
|
|
|
| EMC 1
|
| K. Bowler
|
| Vol #:
|
| 5
|
|
|
| EMC 2
|
| A. Ehrlich
|
| Vol #:
|
| 5
|
|
|
| 2006P-0158
|
| Revoke regulations that provided for the inclusion and addition of sucralose as a non-nutritive sweetener in food
|
|
|
| EMC 6
|
| E. Arellano
|
| Vol #:
|
| 1
|
|
|
| 2006P-0209
|
| Safety or Efficacy of Diastat (diazepam rectal gel), 5 mg/ml, 10mg/2 ml, 15 mg/3 ml and 20 mg/4 ml
|
|
|
| EC 7
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| EC 8
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2006P-0242
|
| Approval of any Budesonide Inhalation Suspension Product using Pulmicort Respules
|
|
|
| EC 2
|
| Mr. Dave Lowe
|
| Vol #:
|
| 2
|
|
|
| 2006P-0245
|
| Exclusivity Determination for Risperidone
|
|
|
| EC 8
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2006P-0249
|
| Refain from approving all abbreviated applications for generic enrofloxacin that purport to copy Bayer's Baytril 100 Injectable Solution
|
|
|
| EC 1
|
| Mr. David Lowe
|
| Vol #:
|
| 1
|
|
|
| EC 2
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2006P-0251
|
| Label change or removal from the market of the psychotropic drug Depakote
|
|
|
| EC 3
|
| Mr. Dave Lowe
|
| Vol #:
|
| 1
|
|
|
| 2006V-0216
|
| Laser Light Show
|
|
|
| VRA 1
|
| FDA/CDRH to UniversalStudios Florida
|
| Vol #:
|
| 1
|
|